SWK Holdings Provides Portfolio Update
Rhea-AI Summary
SWK Holdings (NASDAQ:SWKH) has provided a comprehensive portfolio update highlighting significant transactions from Q4 2024. The company made several new originations, including a $5.0M advance to Journey Medical, $0.6M to Biotricity (with 600,000 warrants), an $8.0M senior secured loan to Triple Ring Technologies, $2.5M to SKNV, a $25.7M facility expansion with Eton (with 289,736 warrants), and $2.5M to MedMinder.
On the repayments side, SWK received $4.1M from Exeevo's asset sale, $13.0M from Biolase's bankruptcy estate, $1.9M from Trio Healthcare, $4.2M from Veru's FC2 Female Condom sale, and $12.2M final payment from Moleculight. Additional payments are expected in 2025 from various sources, including Exeevo earn-outs and the Biolase estate.
Positive
- New loan originations totaling $44.3M across multiple companies
- Received significant repayments totaling $35.4M
- Acquired warrant positions in Biotricity and Eton
- Additional payments expected in 2025 from multiple sources
Negative
- Biolase bankruptcy involvement indicates a troubled investment
- Several early repayments might impact future interest income
News Market Reaction – SWKH
On the day this news was published, SWKH declined 1.43%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
DALLAS, TX / ACCESSWIRE / January 6, 2025 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update for material events occurring since September 30, 2024.
Originations
In November, SWK advanced
In November, as part of a broader amendment SWK advanced
In December, SWK closed an
In December, SWK advanced
In December, SWK closed a
In December, SWK advanced
Repayments
In November, as a result of the sale of certain Exeevo assets to a third-party, SWK received a
In November, SWK received a
In December, SWK received a
In December, SWK received a
In January, Moleculight made a final payment to SWK totaling
About SWK Holdings Corporation
SWK Holdings Corporation is a life science focused specialty finance company partnering with small- and mid-sized commercial-stage healthcare companies. SWK provides non-dilutive financing to fuel the development and commercialization of lifesaving and life-enhancing medical technologies and products. SWK's unique financing structures provide flexible financing solutions at an attractive cost of capital to create long-term value for all SWK stakeholders. SWK's solutions include structured debt, traditional royalty monetization, synthetic royalty transactions, and asset purchases typically ranging in size from
SWK also owns Enteris BioPharma, a clinical development and manufacturing organization providing development services to pharmaceutical partners as well as innovative formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence® platform. Additional information on the life science finance market is available on the Company's website at www.swkhold.com.
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect SWK's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" and elsewhere in SWK's Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein, could affect the Company's future financial results and could cause actual results to differ materially from those expressed in such forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause the Company's actual results to differ materially from expected and historical results. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
For more information, please contact:
Investor Relations and Media
Ira M. Gostin
investorrelations@swkhold.com
775-391-0213
SOURCE: SWK Holdings Corp.
View the original press release on accesswire.com